Gilenya (je-LEN-yah, fingolimod) is the first ORAL drug to reduce relapses in relapsing-remitting multiple sclerosis (MS)

April 2011

Gilenya (je-LEN-yah, fingolimod) is the first ORAL drug to reduce relapses in relapsing-remitting multiple sclerosis (MS).

It's an immune modulator and might help prevent white blood cells from entering the CNS and damaging it.

But don't expect to see Gilenya used first-line.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
200+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get quote

Table of Contents

Osteoporosis more reasons to advocate for judicious use of PPIs
Supplements potassium iodide for radiation exposure
NSAIDs combination NSAID called Vimovo that contains naproxen plus the proton pump inhibitor, esomeprazole
Infectious Diseases avoid quinolones for UNCOMPLICATED urinary tract infections (UTIs) in women
Women's Health questions about drug safety in pregnancy
Benzodiazepines how to use benzodiazepines appropriately
Respiratory & Allergy whether patients on stimulants for ADHD can take cough, cold, and allergy meds containing decongestants
Multiple Sclerosis Gilenya (je-LEN-yah, fingolimod) is the first ORAL drug to reduce relapses in relapsing-remitting multiple sclerosis (MS)
Anticoagulants how long to continue warfarin after a venous thromboembolism (VTE)
STIs Canada's latest sexually transmitted infections (STIs) guidelines
Oral Health which patients should get antibiotics before dental work